WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Boston Scientific pushes its $14.5B Penumbra close into early 2027 Boston Scientific puts the August cyberattack at $150M of lost Q3 sales electroCore files a 510(k) for Quell in chemotherapy-induced neuropathy GT Metabolic raises a Series C from J.P. Morgan for magnetic anastomosis B. Braun pulls three lots of dialysis bloodline sets over a skipped bonding step RadNet pays $350M plus 5 million shares for teleradiology provider Onrad FDA opens comment on an electronic submission template for IDE applications Vincora wins an IDE to implant artificial chordae on a beating heart OrthoPediatrics clears a retrograde femur nail in 7 to 11 mm diameters Boston Scientific pushes its $14.5B Penumbra close into early 2027 Boston Scientific puts the August cyberattack at $150M of lost Q3 sales electroCore files a 510(k) for Quell in chemotherapy-induced neuropathy GT Metabolic raises a Series C from J.P. Morgan for magnetic anastomosis B. Braun pulls three lots of dialysis bloodline sets over a skipped bonding step RadNet pays $350M plus 5 million shares for teleradiology provider Onrad FDA opens comment on an electronic submission template for IDE applications Vincora wins an IDE to implant artificial chordae on a beating heart OrthoPediatrics clears a retrograde femur nail in 7 to 11 mm diameters

Series C

GT Metabolic raises a Series C from J.P. Morgan for magnetic anastomosis

MedDevice Startups Staff · 22 hrs ago · 2 min read · Via GT Metabolic Solutions release via Business Wire

GT Metabolic Solutions raised a Series C growth investment led by J.P. Morgan Life Sciences Private Capital. The company announced the round on October 28 and did not disclose the amount. It describes the round as its first institutional financing partnership.

The Minneapolis company makes magnetic compression devices that form gastrointestinal anastomoses without incisions, sutures or staples. FDA granted a De Novo in September 2024 for its MagDI system in side-to-side duodeno-ileal anastomosis, four years after the company was founded. GT Metabolic says it is the first to hold both a De Novo grant and a 510(k) clearance for magnet-based compression anastomosis, and lists sites in Minneapolis, San Jose and Montreal.

A growth round with no number on it, led by a bank's private capital arm rather than a device fund, usually means the money is going into commercial build rather than the next trial.

Questions & Answers

Who led GT Metabolic Solutions' Series C round?

J.P. Morgan Life Sciences Private Capital led the GT Metabolic Solutions Series C growth investment announced on October 28, 2026. GT Metabolic did not disclose the amount raised and named no other investors.

What does GT Metabolic Solutions make?

GT Metabolic Solutions, based in Minneapolis, makes magnetic compression devices that create gastrointestinal anastomoses without incisions, sutures or staples. Its MagDI system received an FDA De Novo grant in September 2024 for side-to-side duodeno-ileal anastomosis.

Does GT Metabolic Solutions have FDA authorization?

Yes. FDA granted GT Metabolic Solutions a De Novo marketing authorization in September 2024 for the MagDI system, and the company says it holds both a De Novo grant and a 510(k) clearance for magnet-based compression anastomosis.

← Back to Fundraising